IL-13 and IL-13Rα1 expression in patients with Hodgkin lymphoma
| Case no. . | Diagnosis . | Age/sex . | Stage . | IL-13 + HRS cells . | IL-13Rα1 + HRS cells . |
|---|---|---|---|---|---|
| 1 | NSHL | 16/M | IV B | + | + |
| 2 | NSHL | 24/F | II A | + | + |
| 3 | NSHL | 15/F | II A | + | + |
| 4 | NSHL | 43/M | IV B | + | + |
| 5 | NSHL | 33/M | III B | + | + |
| 6 | NSHL | 30/M | II A | + | + |
| 7 | NSHL | 32/F | II B | + | + |
| 8 | NSHL | 25/F | III B | + | ND |
| 9 | NSHL | 27/F | II A | + | + |
| 10 | NSHL | 22/M | III B | + | U |
| 11 | NSHL | 34/M | III A | + | + |
| 12 | NSHL | 19/M | III A | + | + |
| 13 | NSHL | 81/F | II A | + | ND |
| 14 | NSHL | 36/M | III B | + | + |
| 15 | NSHL | 31/F | IV A | + | ND |
| 16 | NSHL | NA | NA | + | ND |
| 17 | NSHL | NA | NA | + | + |
| 18 | NSHL, syn | 64/M | III B | − | − |
| 19 | NSHL, syn | 20/F | II A | + | + |
| 20 | NSHL, syn | 35/M | I B | − | + |
| 21 | NSHL, syn | 45/M | III A | + | + |
| 22 | NSHL, syn | 41/F | II A | + | U |
| 23 | NSHL, syn | 25/M | III B | + | + |
| 24 | MCHL | NA | NA | + | + |
| 25 | MCHL | NA | NA | − | − |
| 26 | MCHL | 28/M | II A | + | + |
| 27 | MCHL | 28/M | II B | + | ND |
| 28 | MCHL | 42/M | I A | + | + |
| 29 | MCHL | NA/M | II A | + | ND |
| 30 | MCHL | 42/F | III A | + | + |
| 31 | MCHL | NA/F | II A | + | + |
| 32 | MCHL | 45/M | I A | + | ND |
| 33 | MCHL | 88/M | I A | − | − |
| 34 | LDHL | 54/F | IV B | + | + |
| 35 | LDHL | 65/M | NA | − | + |
| 36 | LDHL | 72/F | IV B | + | + |
| Case no. . | Diagnosis . | Age/sex . | Stage . | IL-13 + HRS cells . | IL-13Rα1 + HRS cells . |
|---|---|---|---|---|---|
| 1 | NSHL | 16/M | IV B | + | + |
| 2 | NSHL | 24/F | II A | + | + |
| 3 | NSHL | 15/F | II A | + | + |
| 4 | NSHL | 43/M | IV B | + | + |
| 5 | NSHL | 33/M | III B | + | + |
| 6 | NSHL | 30/M | II A | + | + |
| 7 | NSHL | 32/F | II B | + | + |
| 8 | NSHL | 25/F | III B | + | ND |
| 9 | NSHL | 27/F | II A | + | + |
| 10 | NSHL | 22/M | III B | + | U |
| 11 | NSHL | 34/M | III A | + | + |
| 12 | NSHL | 19/M | III A | + | + |
| 13 | NSHL | 81/F | II A | + | ND |
| 14 | NSHL | 36/M | III B | + | + |
| 15 | NSHL | 31/F | IV A | + | ND |
| 16 | NSHL | NA | NA | + | ND |
| 17 | NSHL | NA | NA | + | + |
| 18 | NSHL, syn | 64/M | III B | − | − |
| 19 | NSHL, syn | 20/F | II A | + | + |
| 20 | NSHL, syn | 35/M | I B | − | + |
| 21 | NSHL, syn | 45/M | III A | + | + |
| 22 | NSHL, syn | 41/F | II A | + | U |
| 23 | NSHL, syn | 25/M | III B | + | + |
| 24 | MCHL | NA | NA | + | + |
| 25 | MCHL | NA | NA | − | − |
| 26 | MCHL | 28/M | II A | + | + |
| 27 | MCHL | 28/M | II B | + | ND |
| 28 | MCHL | 42/M | I A | + | + |
| 29 | MCHL | NA/M | II A | + | ND |
| 30 | MCHL | 42/F | III A | + | + |
| 31 | MCHL | NA/F | II A | + | + |
| 32 | MCHL | 45/M | I A | + | ND |
| 33 | MCHL | 88/M | I A | − | − |
| 34 | LDHL | 54/F | IV B | + | + |
| 35 | LDHL | 65/M | NA | − | + |
| 36 | LDHL | 72/F | IV B | + | + |
NSHL = nodular sclerosis Hodgkin lymphoma; syn = syncytial variant; MCHL = mixed cellularity Hodgkin lymphoma; LDHL = lymphocyte-depletion Hodgkin lymphoma; U = uninterpretable; ND = not done; NA = not available.